Efficacy and immunogenicity of influenza vaccine in HIV-infected children: A randomized, double-blind, placebo controlled trial

AIDS

Volumn 27, Issue 3, 2013, Pages 369-379

  Madhi, Shabir A ^a,b,c   Dittmer, Sylvia ^d   Kuwanda, Locadiah ^b,c   Venter, Marietjie ^a   Cassim, Haseena ^d   Lazarus, Erica ^d   Thomas, Teena ^d   Liberty, Afaaf ^d   Treurnich, Florette ^a   Cutland, Clare L ^b,c   Weinberg, Adriana ^e   Violari, Avy ^d  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b Vaccine Preventable Diseases   (Australia)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

children; efficacy; HIV; immunogenicity; influenza vaccine; pneumonia; safety

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ANTIVIRAL THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE INDURATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNGEAL ASPIRATION; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SEROCONVERSION; WEAKNESS;

ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HIV SEROPOSITIVITY; HOSPITALIZATION; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PHYLOGENY; PNEUMONIA; SOUTH AFRICA; TREATMENT OUTCOME; VIRUS SHEDDING;

EID: 84872342807     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ab5b2     Document Type: Article

References (42)

1. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000; 137:78-84.
2. Madhi SA, Ramasamy N, Bessellar TG, Saloojee H, Klugman KP. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 2002; 21:291-297.
3. Evans KD, Kline MW. Prolonged influenza A infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 1995; 14:332-334.
4. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57 (RR-7):1-60.
5. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1997; 46:1-25.
6. DAIDS Toxicity Tables. http://rcc.tech-es.com/Docu-ment/ safetyandpharmacovigilance/Toxicity Tables-Pediatri-c-Over3MonthsAge-v03.pdf. [Accessed 26 June 2012].
7. Sanofi. PRODUCT MONOGRAPH VAXIGRIP: inactivated influenza vaccine trivalent types A and B (Split Virion) http://wwwnovaccinecom/pdffiles/vaxigrip- package-insertpdf. [Accessed 21 May 2012].
8. National Institute for Communicable Diseases. Consolidated Influenza Surveillance Weekly Reports. http://www.nicd.ac.za. [Accessed 26 June 2012].
9. Van Kerkhove MD, Mounts AW. 2009 versus 2010 comparison of influenza activity in southern hemisphere temperate countries. Influenza Other Respir Viruses 2011; 5:375-379.
10. Glencross D, Scott LE, Jani IV, Barnett D, Janossy G. CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4R T-cell enumeration. Cytometry 2002; 50:69-77.
11. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599.
12. Neuzil KM, Mellen BG, Wright PF, Mitchel EFJ, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225-231.
13. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A 2009; 106:8701-8706.
14. Huang JW, Yang JM. Changed epitopes drive the antigenic drift for influenza A (H3N2) viruses. BMC Bioinformatics 2011; 12 (Suppl 1):S31.
15. Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology 2001; 289:74-85.
16. Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adju-vanted H1N12009 pandemic vaccine:a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012; 30:3389-3394.
17. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010; 10:499-503.
18. Cagigi A, Palma P, Nilsson A, Di Cesare S, Pensieroso S, Kakoulidou M, et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. AIDS 2010; 24:2075-2080.
19. Pallikkuth S, Kanthikeel SP, Silva SY, Fischl M, Pahwa R, Pahwa S. Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. J Allergy Clin Immunol 2011; 128:1279-1285.
20. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virus. J Hyg (Lond) 1972; 70:767-777.
21. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18.
22. Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982; 116:228-242.
23. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediat Infect Dis J 2011; 30:1081-1085.
24. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitaya-sunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042-1053.
25. Lyall EG, Charlett A, Watkins P, Zambon M. Response to influenza virus vaccination in vertical HIV infection. Arch Dis Child 1997; 76:215-218.
26. Jackson CR, Vavro CL, Valentine ME, Pennington KN, Lanier ER, Katz SL, et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 1997; 16:200-204.
27. Ramilo O, Hicks PJ, Borvak J, Gross LM, Zhong D, Squires JE, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996; 15:197-203.
28. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994; 13:206-211.
29. Kosalaraksa P, Srirompotong U, Newman RW, Lumbiganon P, Wood JM. Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine 2011; 29:3055-3060.
30. Machado AA, Machado CM, Boas LS, Lopes MC, Gouvea Ade F, Succi RC, et al. Immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents. AIDS Res Hum Retroviruses 2011; 27:999-1003.
31. Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active anti-retroviral therapy. Mem Inst Oswaldo Cruz 2007; 102:501-508.
32. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-137.
33. Vigano A, Zuccotti GV, Pacei M, Erba P, Castelletti E, Giacomet V, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:289-296.
34. Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006; 78:440-445.
35. Vigano A, Giacomet V, Pariani E, Giani E, Manfredini V, Bedogni G, et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin Vaccine Immunol 2011; 18:1503-1509.
36. Phongsamart W, Sirisanthana V, Wittawatmongkol O, Malee-satharn A, Sudjaritruk T, Chearskul P, et al. Immunogenicity and safety ofmonovalent influenzaA (H1N1) 2009in HIV-infected Thai children. Vaccine 2011; 29:8705-8711.
37. Weinberg A, Song LY, Fenton T, Nachman SA, Read JS, Patter-son-Bartlett J, et al. T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res Hum Retroviruses 2010; 26:51-59.
38. Levin MJ, Song LY, Fenton T, Nachman S, Patterson J, Walker R, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-4217.
39. Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patter-son-Bartlett J, et al. Antiinfluenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010; 55:189-196.
40. Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, et al. Safety and immunogenicity of a monovalent MF59(R)-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Biologicals 2012; 40:134-139.
41. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406-1416.
42. M'Rabet L, Vos AP, Boehm G, Garssen J. Breast-feeding and its role in early development of the immune system in infants: consequences for health later in life. J Nutr 2008; 138:1782S-1790S.